drugset
drugset / Trial / NCT04096287

Safety and Tolerability of PNT001 in Healthy Adults

NCT04096287 ↗

Phase 1 Completed 49 enrolled Pinteon Therapeutics, Inc
RandomizedSequentialDouble-blindTreatment

Summary

This first in human study is a multi-center, randomized, double-blind, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous PNT001 in healthy adult participants.

Timeline

Start
2019-09-17
Primary completion
2021-02-15
Completion
2021-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject PNT001 Unknown 33 mg Intravenous
Subject PNT001 Unknown 100 mg Intravenous
Subject PNT001 Unknown 300 mg Intravenous
Subject PNT001 Unknown 900 mg Intravenous
Subject PNT001 Unknown 2700 mg Intravenous
Subject PNT001 Unknown 4000 mg Intravenous

Indications

No indication recorded.